Rep turnover in India "as high as 30-40%" as expanding firms compete with other sectors
This article was originally published in Scrip
The Indian pharmaceutical industry, seen as a hotbed of future growth and with several success stories to its credit, appears to have got it right in most areas of operation. But there are worrying signs that it may not be up to scratch when it comes to people issues, with overall employee attrition rates in the Indian industry well above global rates.
You may also be interested in...
Gland Pharma, controlled by Chinese group Fosun, makes shining debut on Indian stock markets despite a lukewarm response to its IPO. Will the buoyant market sentiment sustain amid edgy India-China relations?
A senior executive of Janssen’s supply chain leadership team outlines how the company handled activities in Asia Pacific at the height of the coronavirus outbreak, including ensuring continuous and rapid supplies of critical medicines in China. The company is also prepping against “multiple scenarios” to ensure global access for its potential COVID-19 vaccine.
Expert outlines how pharma can create resilient and secure supply chains and some benefits of localization.